Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles

What other to cognize

• Nan Fung's remaining Oculis involvement of 350,745 shares was valued astatine $9.3 cardinal astatine quarter-end, representing 7.7% of the fund's full AUM and ranking arsenic its fourth-largest holding.

• Top holdings aft the filing:

  • NYSE: EVMN: $33.1 cardinal (27.3% of AUM)

  • NASDAQ: MPLT: $19.7 cardinal (16.3% of AUM)

  • NASDAQ: LBRX: $15.6 cardinal (12.8% of AUM)

  • NASDAQ: OCS: $9.3 cardinal (7.7% of AUM)

  • NASDAQ: INCY: $5.1 cardinal (4.2% of AUM)

• As of June 5, 2026, Oculis shares were trading astatine $11.21 -- down astir 43% implicit the past year, and underperforming the S&P 500 by astir 67 percent points.

Company overview

Company snapshot

Oculis Holding AG is simply a clinical-stage biopharmaceutical institution processing caller topical therapies for ophthalmic and neuro-ophthalmic diseases.

• Oculis targets ophthalmologists and healthcare providers treating patients with diabetic oculus disease, adust eye, and neuro-ophthalmic disorders successful planetary markets.

• Following the late-May 2026 nonaccomplishment of its Phase 3 DIAMOND trials, Oculis is nary longer pursuing FDA support for OCS-01 successful diabetic macular edema. The institution is present concentrating its pipeline connected 2 remaining registrational programs: Privosegtor (PIONEER-1, Phase 3 for optic neuropathies, which holds FDA Breakthrough Therapy Designation) and Licaminlimab (PREDICT-1, Phase 2b for adust oculus disease).

• As of March 31, 2026, the institution reported $277.6 cardinal successful cash, currency equivalents, and short-term investments, providing a backing runway into the 2nd fractional of 2029.

What this transaction means for investors

Nan Fung's Q1 trim of its Oculis involvement looks little similar a ballot of nary assurance and much similar regular portfolio rebalancing. But the discourse astir Oculis has grown considerably much analyzable since the extremity of Q1.

On May 29, 2026, Oculis announced that its 2 Phase 3 DIAMOND trials of OCS-01 -- a topical oculus driblet for diabetic macular edema -- failed to conscionable their superior imaginativeness endpoints. The institution volition not prosecute FDA support for that denotation and has pivoted its resources toward its 2 remaining programs: Privosegtor, which holds an FDA Breakthrough Therapy Designation for optic neuritis, and Licaminlimab for adust oculus disease. That late-May setback explains overmuch of the melodramatic banal descent that has pushed OCS down astir 43% implicit the past year. From that perspective, Nan Fung's Q1 merchantability -- adjacent the $26 scope based connected quarterly mean pricing, overmuch higher than today’s stock terms of $11-and-change -- predated the atrocious quality and looks comparatively good timed.